169 related articles for article (PubMed ID: 24314590)
1. Comparison of 24-month outcomes in chelated and non-chelated lower-risk patients with myelodysplastic syndromes in a prospective registry.
Lyons RM; Marek BJ; Paley C; Esposito J; Garbo L; DiBella N; Garcia-Manero G
Leuk Res; 2014 Feb; 38(2):149-54. PubMed ID: 24314590
[TBL] [Abstract][Full Text] [Related]
2. Relation between chelation and clinical outcomes in lower-risk patients with myelodysplastic syndromes: Registry analysis at 5 years.
Lyons RM; Marek BJ; Paley C; Esposito J; McNamara K; Richards PD; DiBella N; Garcia-Manero G
Leuk Res; 2017 May; 56():88-95. PubMed ID: 28242540
[TBL] [Abstract][Full Text] [Related]
3. Adequate iron chelation therapy for at least six months improves survival in transfusion-dependent patients with lower risk myelodysplastic syndromes.
Delforge M; Selleslag D; Beguin Y; Triffet A; Mineur P; Theunissen K; Graux C; Trullemans F; Boulet D; Van Eygen K; Noens L; Van Steenweghen S; Lemmens J; Pierre P; D'hondt R; Ferrant A; Deeren D; Van De Velde A; Wynendaele W; André M; De Bock R; Efira A; Breems D; Deweweire A; Geldhof K; Pluymers W; Harrington A; MacDonald K; Abraham I; Ravoet C
Leuk Res; 2014 May; 38(5):557-63. PubMed ID: 24661630
[TBL] [Abstract][Full Text] [Related]
4. Impact of treatment with iron chelation therapy in patients with lower-risk myelodysplastic syndromes participating in the European MDS registry.
Hoeks M; Yu G; Langemeijer S; Crouch S; de Swart L; Fenaux P; Symeonidis A; Čermák J; Hellström-Lindberg E; Sanz G; Stauder R; Holm MS; Mittelman M; Mądry K; Malcovati L; Tatic A; Almeida AM; Germing U; Savic A; Šimec NG; Culligan D; Itzykson R; Guerci-Bresler A; Slama B; Droste J; van Marrewijk C; van de Loosdrecht A; Blijlevens N; van Kraaij M; Bowen D; de Witte T; Smith A;
Haematologica; 2020 Mar; 105(3):640-651. PubMed ID: 31278207
[TBL] [Abstract][Full Text] [Related]
5. Improved survival in MDS patients receiving iron chelation therapy - a matched pair analysis of 188 patients from the Düsseldorf MDS registry.
Neukirchen J; Fox F; Kündgen A; Nachtkamp K; Strupp C; Haas R; Germing U; Gattermann N
Leuk Res; 2012 Aug; 36(8):1067-70. PubMed ID: 22564985
[TBL] [Abstract][Full Text] [Related]
6. Optimizing therapy for iron overload in the myelodysplastic syndromes: recent developments.
Leitch HA
Drugs; 2011 Jan; 71(2):155-77. PubMed ID: 21275444
[TBL] [Abstract][Full Text] [Related]
7. Iron status and treatment modalities in transfusion-dependent patients with myelodysplastic syndromes.
Delforge M; Selleslag D; Triffet A; Mineur P; Bries G; Graux C; Trullemans F; MacDonald K; Abraham I; Pluymers W; Ravoet C
Ann Hematol; 2011 Jun; 90(6):655-66. PubMed ID: 21318574
[TBL] [Abstract][Full Text] [Related]
8. Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM (Groupe Francophone des Myélodysplasies).
Rose C; Brechignac S; Vassilief D; Pascal L; Stamatoullas A; Guerci A; Larbaa D; Dreyfus F; Beyne-Rauzy O; Chaury MP; Roy L; Cheze S; Morel P; Fenaux P;
Leuk Res; 2010 Jul; 34(7):864-70. PubMed ID: 20129667
[TBL] [Abstract][Full Text] [Related]
9. Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload.
Nolte F; Höchsmann B; Giagounidis A; Lübbert M; Platzbecker U; Haase D; Lück A; Gattermann N; Taupitz M; Baier M; Leismann O; Junkes A; Schumann C; Hofmann WK; Schrezenmeier H
Ann Hematol; 2013 Jan; 92(2):191-8. PubMed ID: 23073603
[TBL] [Abstract][Full Text] [Related]
10. Evolution of iron overload in patients with low-risk myelodysplastic syndrome: iron chelation therapy and organ complications.
Remacha ÁF; Arrizabalaga B; Villegas A; Durán MS; Hermosín L; de Paz R; Garcia M; Diez Campelo M; Sanz G;
Ann Hematol; 2015 May; 94(5):779-87. PubMed ID: 25516455
[TBL] [Abstract][Full Text] [Related]
11. Transfusional iron overload in patients with myelodysplastic syndromes: A 10-year retrospective survey from a French general hospital.
Bauduer F; Recanzone H
Transfus Clin Biol; 2020 Aug; 27(3):128-132. PubMed ID: 32561328
[TBL] [Abstract][Full Text] [Related]
12. Toward resolving the unsettled role of iron chelation therapy in myelodysplastic syndromes.
Merkel DG; Nagler A
Expert Rev Anticancer Ther; 2014 Jul; 14(7):817-29. PubMed ID: 24641787
[TBL] [Abstract][Full Text] [Related]
13. Controversies surrounding iron chelation therapy for MDS.
Leitch HA
Blood Rev; 2011 Jan; 25(1):17-31. PubMed ID: 21030120
[TBL] [Abstract][Full Text] [Related]
14. Overall survival in lower IPSS risk MDS by receipt of iron chelation therapy, adjusting for patient-related factors and measuring from time of first red blood cell transfusion dependence: an MDS-CAN analysis.
Leitch HA; Parmar A; Wells RA; Chodirker L; Zhu N; Nevill TJ; Yee KWL; Leber B; Keating MM; Sabloff M; St Hilaire E; Kumar R; Delage R; Geddes M; Storring JM; Kew A; Shamy A; Elemary M; Lenis M; Mamedov A; Ivo J; Francis J; Zhang L; Buckstein R
Br J Haematol; 2017 Oct; 179(1):83-97. PubMed ID: 28677895
[TBL] [Abstract][Full Text] [Related]
15. Iron chelation in MDS: still a controversial issue.
Neukirchen J
Leuk Res; 2014 Feb; 38(2):145-6. PubMed ID: 24373456
[No Abstract] [Full Text] [Related]
16. Objectives of iron chelation therapy in myelodysplastic syndromes: more than meets the eye?
Pullarkat V
Blood; 2009 Dec; 114(26):5251-5. PubMed ID: 19710499
[TBL] [Abstract][Full Text] [Related]
17. Observational Monitoring of Patients with Aplastic Anemia and Low/Intermediate-1 Risk of Myelodysplastic Syndromes Complicated with Iron Overload.
Du Y; Long Z; Chen M; Han B; Hou B; Feng F
Acta Haematol; 2017; 138(2):119-128. PubMed ID: 28866669
[TBL] [Abstract][Full Text] [Related]
18. Survival outcomes in iron chelated and non-chelated patients with lower-risk myelodysplastic syndromes: Review and pooled analysis of observational studies.
Abraham I; Yami MA; Yun S; Kim HJ; Vincelette ND; McBride A; MacDonald K
Leuk Res; 2017 Jun; 57():104-108. PubMed ID: 28343141
[No Abstract] [Full Text] [Related]
19. Can iron overload in patients with lower-risk myelodysplastic syndromes be reduced using erythropoiesis-stimulating agents?
Tsang E; Leitch HA
Ann Hematol; 2016 Jan; 95(1):73-78. PubMed ID: 26453076
[TBL] [Abstract][Full Text] [Related]
20. Iron-chelating therapy with deferasirox in transfusion-dependent, higher risk myelodysplastic syndromes: a retrospective, multicentre study.
Musto P; Maurillo L; Simeon V; Poloni A; Finelli C; Balleari E; Ricco A; Rivellini F; Cortelezzi A; Tarantini G; Villani O; Mansueto G; Milella MR; Scapicchio D; Marziano G; Breccia M; Niscola P; Sanna A; Clissa C; Voso MT; Fenu S; Venditti A; Santini V; Angelucci E; Levis A
Br J Haematol; 2017 Jun; 177(5):741-750. PubMed ID: 28419408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
